ByTrending Posts
Can Ianalumab Anchor Novartis’ Next Growth Cycle as…
23 Jan 2026 Executive Summary Novartis has secured Breakthrough Therapy designation for ianalumab, a late-stage immunology asset, reinforcing…
Can AI Become the Backbone of Global Health…
Executive Summary The Bill & Melinda Gates Foundation and OpenAI have announced a $50 million public–private initiative, Horizon1000,…
Is AI Becoming Big Pharma’s Frontline Tool for…
Executive Summary Bristol Myers Squibb (BMS) has entered a strategic partnership with Microsoft to advance AI-driven early detection…
Is JPM 2026 the Moment Biopharma Finally Reset…
January 2026 — San Francisco | Global — The 44th Annual J.P. Morgan Healthcare Conference (JPM 2026) marked…
How Might Trump’s Strategic Healthcare Proposal Impact Innovation…
January 22, 2026 — Global — BioNexAI Market Insights reports that U.S. President Donald J. Trump has introduced…
How Will Hippocratic AI Leverage Grove AI to…
January 22, 2026 — Global — BioNexAI Market Insights reports that Hippocratic AI, a leading AI innovator, has…
Is Novartis Bolstering Its Radioligand Oncology Pipeline at…
Basel / San Francisco | January 2026 Novartis has expanded its precision oncology strategy with a global license and…
Is Pfizer’s $10 Billion Metsera Acquisition at JPM2026…
San Francisco / New York | January 2026 Pfizer has made a decisive strategic move to expand its…
Is Amgen Bolstering Its Oncology Pipeline at JPM…
Thousand Oaks, U.S. | January 2026 Amgen has expanded its oncology growth strategy with the acquisition of Dark…
Trending Posts
Latest Stories
Ardent Health’s Hellocare.ai Virtual Nursing Play: 20% Readmission Slash or AI Overreach in Care?
Ardent Health’s March 3-4, 2026, partnership with Hellocare.ai deploys AI modules for virtual nursing, telehealth,…
VA’s Nationwide Ambient AI Scribe Rollout: Burnout Buster or Documentation Digitized Trap?
The U.S. Department of Veterans Affairs on March 4, 2026, greenlit ambient scribe AI from…
Gilead’s $8B Arcellx CAR-T Swoop & Lilly Zepbound Triumph: Obesity/CAR-T Mania or Bubble Burst Ahead?
Gilead’s March 2026 $8B acquisition of Arcellx—securing CAR-T anito-cel for multiple myeloma with 73% ORR…
FDA’s AZ/GSK Biologics Rejections: Data Integrity Wake-Up or R&D Overhaul Catalyst?
FDA rejection letters issued March 3-4, 2026, flagged data integrity lapses in AstraZeneca’s subcutaneous tezepelumab…
Gallery
